Comparison of treat-and-extend dosing regimens and visual outcomes showed that intravitreal aflibercept was effective over 2 years, with more than half of patients achieving a last treatment interval of 12 weeks or longer.
“Proactive T&E regimens can help identify patents who require frequent treatments vs. those who can be extended. In addition, they offer potential advantages such as reduced treatment burden, fewer visits and can be applied in real-world clinical practice,” Paul Mitchell, MD, said in a poster presented at the virtual Association for Research in Vision and
Uncategorized